AlbuVoid™ - Albumin Depletion and Low Abundance Protein Enrichment Kit from Serum, Plasma, Tissues And Culture Media
AlbuVoid™ - Albumin Depletion Plus Low Abundance Serum Protein Enrichment
- Albumin voids in flow-through >95%, with <30 minute bind/wash/elute protocol
- Low abundance enrichment equivalent or better than hexa-peptides or antibodies
- Disposable, cost-effective, no column regeneration or cross-contamination
- Mild elution maintains tertiary structure and simple transfer to secondary analysis
- The eluted fractions retain their enzymatic and biological activity
- Removes albumin from many species including human, mouse, sheep, bovine, goat, rat, calf, cell culture.
- The eluted fraction is compatible with LC-MS, activity based protein profiling and proteomic studies.
AlbuVoid™ is a albumin depletion reagent kit. It removes albumin from serum and plasma samples while concentrating low abundance, and/or low molecular weight proteins. The AlbuVoid™ protocol uses mild buffers; the protocol conditions are so gentle that native enzyme activity is retained in elution fractions. AlbuVoid™ considerably enhances resolution of proteins below 50 kD, a limitation of alternate enrichment protocols.
AlbuVoid™ does not bind albumin. All other proteins(except albumin) in the sample binds to AlbuVoid™ and then you can elute off all the proteins minus the albumin. Resulting in low abundance serum protein enrichment. It is ideal for applications involving biomarker discovery, enzyme assays, toxicological studies for new drugs, protein profiling using SELDI analysis, protein array pixelation ,1D and 2D gel electrophoresis, LC/MS, and MALDI-TOF MS and cytokines research.
AlbuVoid™ derives from a silica-based library of individual mixed-mode polymeric ligands. The library was designed to facilitate weak binding of proteins, allowing for rapid elution from the matrix without any foreknowledge of the variety of proteins contained in the starting sample. Because of its specific binding properties, AlbuVoid™ depletes high abundance proteins in serum like albumin while improving the resolution of less abundant serum proteins.
Biotech Support Group also has AlbuSorb™ for albumin depletion plus low abundance serum protein enrichment. Both AlbuSorb™ and AlbuVoid™ are available in AlbuTrial kit™. AlbuTrial kit™ includes 1 gm of Albusorb™ and 5 Preps of AlbuVoid™ with respective buffers.
Click herefor AlbuVoid™ Product Sheet
Click herefor AlbuVoid™ On Bead Digestion Protocol
Grubbs, J. K., et al. "Investigation of the efficacy of albumin removal procedures on porcine serum proteome profile1." (2015).
Discovery of Functional Serum Biomarkers Using AlbuVoid™ Enrichment and the ArrayBridge PEP Profiling Platform.Personal communication, Xing Wang, Ph.D., ArrayBridge (St. Louis, MO), manuscripts in process.
Serum Profiling Making Mark on Predictive Medicine
Vicki Glaser.Genetic Engineering & Biotechnology News. 2011;31(7):1-55.
Espes, Daniel, Joey Lau, and Per-Ola Carlsson. "Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes." Diabetologia(2013): 1-4.
Patent - Secretome Sample Preparation
Narain, Niven Rajin, and Paula Patricia Narain. "COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER." U.S. Patent No. 20,150,023,949. 22 Jan. 2015.
Narain, Niven Rajin, Rangaprasad Sarangarajan, and Vivek K. Vishnudas. "INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF." U.S. Patent No. 20,120,258,874. 11 Oct. 2012.
Narain, Niven Rajin, Rangaprasad Sarangarajan, Vivek K. Vishnudas, and Michael Andrew Kiebish. "USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS AND IN THE DIAGNOSIS AND MONITORING OF CARDIOMYOPATHY AND CARDIOVASCULAR DISEASE." U.S. Patent 20,140,100,128, issued April 10, 2014.
On-Bead Digestion Protocols For LC-MS Proteomic Workflows
New on-bead digestion for LC-MS applications for proteomic studies
US HUPO 2014. Frontiers in Proteomics: Advancing Biology through Technology and Computation.
AlbuVoid™ abstract entitled "Improved proteomic enrichment and workflow strategies", poster board 089 presented at US HUPO 2014